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ABSTRACT  Currently, it is widely acknowledged that a proactive anticancer immunosurveillance 
mechanism takes part in the rejection of neoplastic lesions before they progress towards a benign 
or malignant tumour. However in cases of very aggressive neoplastic lesions consisting of cells 
with high mutational diversity, cancer cell variants might be formed that are capable of evading 
host defence systems against uncontrolled proliferation and anticancer immunosurveillance. This 
is mainly accomplished through the exhibition of low immunogenicity, which is a particularly 
important stumbling block in the revival of long-lasting as well as stable anticancer immunity. 
Recently, it has emerged emphatically that inciting a cancer cell death routine, associated with 
the activation of danger signalling pathways evoking emission of damage-associated molecular 
patterns (DAMPs), markedly increases the immunogenicity of dying cancer cells. This cell death 
pathway has been termed “immunogenic cell death” (ICD). In the present review we introduce this 
concept and discuss its characteristics in detail. We also discuss in detail the various molecular, 
immunological and operational determinants of ICD. 
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Immunogenic cell death: the concept
Most newly formed neoplastic lesions in our body are readily 
rejected by the host defence system. It is now widely acknowledged 
that a proactive anticancer immunosurveillance mechanism takes 
part in rejection of neoplastic lesions before they progress towards 
a benign or malignant tumour (Dunn et al., 2002, Senovilla et al., 
2012). However in cases of very aggressive neoplastic lesions 
consisting of cells with high mutational diversity; cancer cell vari-
ants might be formed that are capable of evading host defence 
systems against uncontrolled proliferation and anticancer immu-
nosurveillance (Dunn et al., 2002, Zitvogel et al., 2006). In such a 
scenario, the host immune system might start acting as a “natural 
selection force” by performing cancer immunoediting, which might 
lead to the formation of cancer cells that are highly immunoevasive 
and capable of resisting antitumour immunity (Dunn et al., 2002). 
Overall resistance against the host anticancer immunosurveillance 
and antitumour immunity is achieved by various mechanisms 
including, acquaintance of low immunogenicity, ability to induce 
immunotolerance or active immunosuppression, and ability to 
resist immune cell-mediated lysis (Dunn et al., 2002, Garg et al., 
2013b, Zitvogel et al., 2006). Here, the exhibition of low immuno-
genicity is a particularly important stumbling block in the revival 
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of long-lasting as well as stable anticancer immunity. Therefore it 
had been proposed recently that, one route through which one can 
revive potent anticancer immune responses, is by accentuating the 
general immunogenicity of cancerous cells (Casares et al., 2005). 
Research published over the last decade has established that 
spatiotemporally defined emission of danger signals or damage-
associated molecular patterns (DAMPs) as a part of an elaborate 
danger signalling module can help in elevating the immunogenicity 
of dying, stressed or dead cancer cells – a concept pioneered by 
the labs of Guido Kroemer and Laurence Zitvogel (Kroemer et al., 
2013). Operationally, it has been shown that inciting a cancer cell 
death routine, associated with the activation of danger signalling 
pathways evoking the pre-mortem emission of DAMPs, markedly 
increases the immunogenicity of these dying cells (Kepp et al., 
2014). This cell death pathway has been termed as ‘immunogenic 
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cell death (ICD)’ (Kepp et al., 2014; Kroemer et al., 2013; Garg 
et al., 2014). ICD has the ability to convert dying or dead cancer 
cells into a “vaccine” capable of inducing anticancer immunity in 
absence of any additional adjuvants (Galluzzi et al., 2014). 
ICD is highly stressor-dependent (Fig. 1) primarily because its 
execution requires elicitation of oxidative-endoplasmic reticulum 
(ER) stress (Garg et al., 2012c), or at least almost simultaneous 
induction of reactive oxygen species (ROS) and ER stress (Pana-
retakis et al., 2009). The concomitant induction of oxidative stress 
and ER stress is crucial for elicitation of danger signalling pathways 
mediating the trafficking and emission of danger signals or DAMPs 
(Galluzzi et al., 2012, Garg et al., 2012c). The first systematic screen-
ing for ICD inducers (Obeid et al., 2007) recognised, anthracyclines, 
mitoxantrone, and radiotherapy (Fig. 1), as potent inducers of ICD 
in cancer (Box 1). Since this screening study, other novel and highly 
efficacious ICD inducers have been identified by targeted studies 
(Fig. 1), which include various assorted chemotherapeutics, certain 
targeted therapeutics, various physical modalities, certain com-
ponents of Chinese traditional medicine, certain oncolytic viruses 
and hypericin-based photodynamic therapy (Hyp-PDT) (Box 1). 
However, some inducers in this list, such as mitoxantrone, Hyp-PDT, 
shikonin, cardiac glycosides and bortezomib, have unique proper-
ties that make them ‘near-to-ideal’ inducers of ICD (Krysko et al., 
2012). Importantly, Hyp-PDT is the first ever ICD inducer shown 
to specifically target the ER via oxidative stress (in a ‘focused’, 
on-target manner) thereby inducing a molecularly superior form 
of ICD, both in terms of kinetics as well as mechanics of danger 
signalling (Garg et al., 2012c, Krysko et al., 2012). On the other 
hand, mitoxantrone is currently the most studied ICD inducer, in 
terms of both extensive in vivo immunological knowledge about 
its anticancer activity and its clinical immunostimulatory activity 
(Kepp et al., 2014). Mitoxantrone (or anthracyclines in general) 
has played an important role in characterizing the mechanics and 
kinetics of ICD (Kroemer et al., 2013, Krysko et al., 2012). But it 
is expected that as more ICD inducers are discovered, we would 
learn more about ICD, its complexity and whether certain danger 
or immunological signalling processes are broadly applicable to 
ICD or ICD inducer-specific.
Of note, the pioneering (as well as a large portion of the follow-
up) research on ICD characterized it largely as an apoptotic yet 
immunogenic form of cell demise (Casares et al., 2005, Obeid et 
al., 2007). However, it has now started to emerge that another 
programmed form of cell death i.e. programmed necrosis or necrop-
tosis may also associate with ICD. More specifically, it has been 
recently shown that Newcastle disease virus (NDV) can induce 
ICD that is necroptotic in nature (since NDV-induced ICD is devoid 
of apoptotic features, yet is programmed, and can be inhibited by 
Necrostatin-1) (Koks et al., 2015). However the exact molecular 
pathways behind this NDV-induced necroptotic ICD still need further 
attention. Interestingly, NDV is so-far the only known ICD-inducing 
oncolytic virus (Koks et al., 2015) to exhibit the property of inducing 
“abscopal effect”-like anti-tumour immunity (i.e. anticancer immune 
response-based regression of distant tumour sites without gaining 
direct, physical, contact with these sites) (Zamarin et al., 2014). It 
would be interesting to see in future, if other programmed cell death 
routines like mitotic catastrophe, anoikis, paraptosis, pyroptosis 
and entosis can also be associated with ICD. 
Last but not least, as a simple structure–function relationship 
for ICD inducers is virtually non-existent (and perhaps impossible), 
we had proposed a classification scheme for all the ICD inducers. 
This scheme is based on the ability of an ICD inducer to target 
the ER and to induce as many ICD-relevant processes (e.g. cell 
death and danger signalling) as possible, through ER stress (Fig. 
1). As per this scheme, the ICD inducers can be classified as Type 
I and Type II (Dudek et al., 2013, Garg et al., 2014, Krysko et al., 
2012) (Fig. 1; Box 1). Here, Type I ICD inducers are modalities 
Fig. 1. The activity of Type I and Type II im-
munogenic cell death (ICD) inducers. Type 
I ICD inducers are modalities that induce cell 
death via non-ER associated targets and dan-
ger signalling via ER stress; however this split 
in targeting might compromise their ability to 
fully target the ER (site of off-target/collateral 
effects). On the other hand, Type II ICD induc-
ers selectively target the ER to induce both 
cell death as well as danger signalling thereby 
causing ICD-associated immunogenicity in 
an ER-focused (on-target) manner. 7A7, anti-
epidermal growth factor receptor antibody; CGs, 
cardiac glycosides; CTX, cyclophosphamide; 
DOXO,  doxorubicin; HHP, high hydrostatic pres-
sure; Hyp-PDT, hypericin-based photodynamic 
therapy; IRR, iradiation (radiotherapy); MTA, 
microwave thermal ablation; MTX, mitoxan-
trone; OXP, oxaliplatin; PAT, patupilone; RLH-L, 
RIG-I-like helicase ligand; Sep, septacidin; UVC, 
UV radiation, C-band.
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that induce cell death via non-ER associated targets and danger 
signalling via ER stress (Fig. 1); however this split in targeting might 
compromise their ability to fully target the ER (site of off-target/
collateral effects) thereby compromising their ability to fully exploit 
ER stress-based danger signalling (Fig. 1). Most of the known ICD 
inducers fall under the category of Type I ICD inducers (Box 1) 
such that they cause cancer cell death by acting on non-ER as-
sociated targets like DNA/chromatin or DNA replication and repair 
machinery proteins, certain cytosolic proteins, mitochondria, various 
cellular membranes and certain surface transmembrane proteins/
channels (Fig. 1). On the other hand, Type II ICD inducers (Box 1) 
selectively target the ER to induce both cell death as well as danger 
signalling thereby causing ICD-associated immunogenicity in an 
ER-focused (on-target) manner (Fig. 1) (Dudek et al., 2013, Garg 
et al., 2014, Krysko et al., 2012). In fact, using our theory of Type 
I/II ICD inducers, a group of researchers recently characterized 
a new Type II ICD inducing chemotherapeutic compound, PtII N-
heterocyclic carbine complex, based on this compounds’ affinity 
with the ER (Wong et al., 2015). This clearly shows that the Type 
I/II ICD inducer concept can be exploited for discovery of new ICD 
inducers based on their preferential targeting of the ER.
Although therapeutically advantageous on many levels, the 
emergence of ICD has been full of controversy. While on one hand 
it has been described by some as a bystander effect yet others 
have raised doubts on its human applicability, pointing it out to be 
a majorly rodent-associated phenomenon. In fact recently ICD 
was reported to be non-existent in a spontaneous mice model 
(Ciampricotti et al., 2012). More specifically, it was shown that in 
a set-up of spontaneous mammary cancer model, the anticancer 
efficacy of both ICD or non-ICD inducers could not be differentiated; 
in both immunocompetent as well as immunodeficient backgrounds 
thereby raising doubts on ICD existence (Ciampricotti et al., 2012). 
However, one must remember that many major determinants 
of cancer immunogenicity had been initially dismissed as non-
existent (due to controversial or contradictory results) only to be 
later established as bona fide entities owing to reporting of strong 
supportive data. The best example of this is, ironically, cancer-
associated antigens (CAAs) or tumour-associated antigens (TAAs) 
themselves, the very entities that form the foundation of cancer 
immunology and immunotherapy. Research done between 1940s 
and 1960s showed that mouse and possibly human cancer cells 
can be recognized by the immune system (Coulie et al., 2014). 
However, in stark contrast, a 1976 study using spontaneous cancer 
models failed to substantiate the role of anticancer immunity and 
BOX 1
SINGLE-AGENT IMMUNOGENIC CELL DEATH INDUCERS [Extended from (Dudek et al., 2013)]
Type I ICD inducers
Chemotherapeutics or targeted therapeutics/drugs
Bleomycin# (Bugaut et al., 2013), Bortezomib (Spisek et al., 2007), Cyclophosphamide** (Schiavoni et al., 2011), Doxorubicin, Idarubicin, 
Mitoxantrone and Epirubicin (Fucikova et al., 2011, Garg et al., 2013a, Garg et al., 2015, Obeid et al., 2007), Oxaliplatin (Martins et al., 2011), 
Patupilone (Senovilla et al., 2012) Septacidin (Sukkurwala et al., 2014), Shikonin (Chen et al., 2012), Vorinostat (West et al., 2013), Wogonin 
(Yang et al., 2012) and Paclitaxel (Garg et al., 2015).
Biological therapeutics/agents
7A7 anti-EGFR antibody (Garrido et al., 2011), RIG-I-like helicases (RLH) Ligand (Duewell et al., 2014) and Clostridium difficile toxin B (Sun 
et al., 2015).
Physico-chemical or mechanical stress-based therapeutics/agents
High Hydrostatic Pressure (Adkins et al., 2014, Fucikova et al., 2014), Microwave Thermal Ablation (Yu et al., 2014), Specific forms of Ra-
diation therapy (Galluzzi et al., 2013, Gameiro et al., 2014, Garg et al., 2015, Obeid et al., 2007, Schildkopf et al., 2011) and UVC irradiation 
(Panaretakis et al., 2009)
Type II ICD inducers
Hypericin-based photodynamic therapy (Hyp-PDT)
(Dudek-Peric et al., 2015, Garg and Agostinis, 2014, Garg et al., 2013b, Garg et al., 2012a, Garg et al., 2012b), PtII N-heterocyclic carbene com-
plex (Wong et al., 2015) and Various Oncolytic Viruses (Kepp et al., 2014, Koks et al., 2015, Pol et al., 2014).
Important notes on ambivalence or exceptions: #Bleomycin is an ambivalent ICD inducer; it induces all the determinants but paradoxically 
increases levels of the immunosuppressive Treg cells; **Cyclophosphamide induces ICD only at metronomic doses; at high doses it can in fact 
be detrimental to the host immune system in general.
Note on upcoming ICD-inducers: Many anticancer agents or therapies have been recently shown to expose ICD-associated DAMPs like surface-
CRT and/or secreted-ATP and/or released-HMGB1. However in many cases, not all ICD-associated DAMPs are checked. On other occasions, 
in vitro DAMPs detection is done but proper in vivo vaccination or anti-tumour immunity analysis is absent. In absence of full-analysis on all of 
the above levels, the agents cannot be classified as bona fide ICD inducers. Please refer to recent guidelines for proper ICD characterization 
(Kepp et al., 2014).
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concluded that CAAs/TAAs might simply be carcinogen-induced 
artifacts (Hewitt et al., 1976). Later, more elaborate analysis 
proved the existence of CAAs/TAAs in murine system (Boon and 
Kellermann, 1977, Boon and Van Pel, 1978) and also proved that 
spontaneous mouse tumours are capable of expressing CAAs/
TAAs however they are comparatively poorly immunogenic (Van 
Pel and Boon, 1982). These developments paralleled or closely 
followed, the discovery and characterization of T cells in 1960s; 
and subsequently the indispensable role of T cells in mediating 
CAA/TAA-specific tumour-rejecting immunity came to be realized 
between 1970s and 1980s (Coulie et al., 2014). All these efforts 
culminated into the characterization of the first murine TAA i.e. 
P91A in 1988 (De Plaen et al., 1988) and the first human TAA i.e. 
melanoma antigen family A, 1 (MAGEA1) in 1991 (van der Brug-
gen et al., 1991). Following these initial breakthroughs, a number 
of CAAs/TAAs have been identified (both in human and murine 
systems) and these have paved way for more advanced concepts 
in the fields of cancer immunology and immunotherapy (Coulie et 
al., 2014). In a very similar fashion, the concept of ‘danger signals’ 
or DAMPs, which is innate to the execution of ICD, was also initially 
dismissed (Pradeu and Cooper, 2012) after being proposed in 1994 
(Matzinger, 1994). It was considered highly controversial because 
it challenged the “self-non-self-theory” of basic immunology stating 
that an immune response is only triggered against a foreign, non-
self-entity but not against an organism’s own components (self) 
(Pradeu and Cooper, 2012). However, since then, the existence 
of danger signals or DAMPs has been firmly established; thanks 
to the initial research into the role of heat-shock proteins acting 
as DAMPs (Pradeu and Cooper, 2012) finally culminating into the 
currently known scenario of DAMPs associated with necrosis, ICD, 
inflammatory or immunopathologies and autoimmune diseases.
To this end, based on all the recent supportive data that has 
been published, the existence of ICD is incontrovertible (Galluzzi 
et al., 2014, Kepp et al., 2014, Kroemer et al., 2013); however it 
is perfectly expected, in a complex disease like cancer, that in 
certain contexts ICD may not happen, either due to defects that 
inhibit or compromise ICD (e.g. incapability of certain drugs to 
induce danger signalling via ER stress or mutations/ablations in 
major danger signalling pathways required for ICD execution) or 
due to the failure of host system to respond to ICD in its entirety 
(e.g. due to defects in immune-receptors crucial for ICD sensing 
or due to natural/drug induced immune-deficiencies) (Garg et al., 
2014, Kroemer et al., 2013, Krysko et al., 2012). In fact, we have 
recently shown that the ICD-resistant phenotype can also stem 
from low endogenous levels of CRT protein in cancer cells which 
results in defective surface-CRT levels, which further causes se-
verely reduced phagocytic clearance of treated cancer cells and 
ultimately leads to the failure of tumor-rejecting immunity (Garg 
et al., in press).
Emission of danger signals: molecular determinants of 
immunogenic cell death
ICD has been found to associate with spatiotemporally defined 
emission of three categories of danger signals or DAMPs i.e. surface 
exposed chaperones (exposed in the pre-apoptotic or pre-mortem 
stage), secreted or released nucleotides/nucleic acids (secreted/
released in pre- or early-apoptotic/mortem stages) and release of 
endogenous toll-like receptor (TLR) agonists (released in mid- or 
post-apoptotic/mortem stages) (Zitvogel et al., 2010) (Garg et al., 
2014, Kroemer et al., 2013).
Surface exposure of particular chaperones
Surface exposure (ecto-) of certain intracellular chaperones like 
calreticulin (CRT), heat shock protein 90 (HSP90) or HSP70 has 
been found to be crucial for the immunogenicity of dying or dead 
cancer cells. On the surface of the stressed/dying cancer cells, 
ecto-CRT has been reported to dock on either lipid rafts or LRP1 
in an inducer/context-dependent fashion (Gardai et al., 2005, Garg 
et al., 2012c), whereas HSP90 tends to bind to LRP1 (Gopal et al., 
2011). However, to date not much is known about HSP70’s docking 
preferences; interestingly, though HSP70’s relatively consistent 
surface distribution as patches and/or small clumps suggests that 
it may not share a docking-entity with ecto-CRT since the latter 
tends to have a more uneven distribution (Gardai et al., 2005, Garg 
et al., 2012b, Garg et al., 2012c). 
Functionally, these chaperone-DAMPs tend to bind various 
immune-receptors like, CD91 and certain scavenger receptors. 
HSP-CD91 binding on immune cells can assist in DC maturation, 
secretion of cytokines and Th cell priming (Pawaria and Binder, 
2011). Of note however, ecto-CRT has been observed in certain 
contexts to not directly mediate DC phenotypic maturation (Garg 
et al., 2013c). Nevertheless, ecto-CRT is an important mediator 
of ICD and an immunogenicity determining DAMP (Garg et al., 
2013a, Obeid et al., 2007). Ecto-CRT functions as an ‘eat me’ 
signal, thereby assisting in the phagocytic uptake of dying cancer 
cells (Chao et al., 2010, Gardai et al., 2005, Garg et al., 2012c, 
Obeid et al., 2007). Moreover, ecto-CRT is capable of inciting the 
production of both IL6 and tumour necrosis factor (TNF) from DCs 
thereby facilitating Th17 polarization (Pawaria and Binder, 2011). 
This observation is further substantiated by a recent study which 
showed that increase in cancer cell-based ecto-CRT associates with 
an increase in DC-based IL6 production which in turn associates 
with increased Th1 polarization, without affecting DC-based IL1b 
or IL10 production (Garg et al., 2013c). Moreover, exogenously 
injected CRT has been observed to promote tumour lymphocyte 
infiltration and increase responsiveness to cancer immunotherapy 
(Wang et al., 2012). Interestingly, a clinical sample study showed 
that overall expression of CRT was associated with increased T cell 
infiltration in stage IIIB colon cancer (Peng et al., 2010). However 
the prognostic impact of overall CRT expression alone might be 
controversial (as more comprehensive studies have described it 
to be in fact a negative prognostic factor) and prone to cohort-
specific effects (Chao et al., 2010; Fucikova et al., 2015). Hence 
for assessing the prognostic effect of ecto-CRT, better detection 
strategies (as differentiating ecto-CRT from endo-CRT is extremely 
difficult in tumour histopathological samples) or better cohort 
stratification strategies might be needed. In fact, the importance of 
cohort stratification strategies for this set-up was described by us 
recently, when we observed that the tumoral CALRhigh-phenotype 
was predictive of positive clinical responses to therapy with only 
ICD inducers like radiotherapy or paclitaxel in non-small cell lung 
or ovarian cancer patients, respectively (but not non-ICD inducer 
like topotecan in ovarian cancer or untreated non-small cell lung 
cancer patients) (Garg et al., in press). Additionally, we found tu-
moral CALR levels to positively correlate with the levels of genes 
relevant for phagosome maturation or processing in only the clinical 
ICD set-up. Interestingly, elevated levels of phosphorylated eIF2a 
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have been shown to correlate with higher ecto-CRT on malignant 
myleoblasts from patients with acute myeloid leukaemia regardless 
of chemotherapy; and higher ecto-CRT correlated with ability of 
autologous T cells to secrete IFN-g on stimulation with blast-derived 
dendritic cell and better overall survival of the patients (Wemeau 
et al., 2010). This observation suggests that ER stress-regulated 
ecto-CRT is associated with the stimulation of anticancer immunity 
and may harbour a prognostic role in cancer patients.
Ecto-HSP90 has also been reported to be a crucial immunoge-
nicity mediator (Spisek et al., 2007). Of note, it has been reported 
in an anti-B cell lymphoma DC vaccination setup, that ecto-HSP90 
tends to correlate better (or at least as much as ecto-CRT) with 
patients responsiveness to therapy (Zappasodi et al., 2010). 
However, recently we observed that in the context of melanoma 
treatment with the chemotherapeutic, melphalan, ecto-HSP90 
despite being exposed, failed to mediate immunogenicity in vivo. 
This shows that ecto-HSP90 might be a more context-dependent 
DAMP than previously recognised (Dudek-Peric et al. 2015). Un-
fortunately, the specific role of ecto-HSP70 during ICD remains 
enigmatic, however at least in a PDT setting ecto-HSP70 might 
favour production of nitric oxide (NO) from innate immune cells 
(Garg et al., 2012b, Garg et al., 2012c, Song et al., 2012). 
In terms of overall ability to phagocytose dying/dead cells, an in 
silico analysis elucidated that CRT possesses close homologues 
of crucial phagocytosis-assisting motifs, whereas HSP70/90 do 
not (Garg et al., 2012b). This observation is substantiated by an 
in vitro/ex vivo study showing that the presence of ecto-CRT cor-
relates better with increase in phagocytosis than either ecto-HSP70 
or ecto-HSP90 (Fucikova et al., 2011).
Secretion or release of nucleotides and/or release of nucleic 
acids
Active secretion of the nucleotide, adenosine triphosphate (ATP) 
(Elliott et al., 2009) and the secretion/release of nucleic acids (Kariko 
et al., 2004) from dying cells are essential for ICD (Ghiringhelli et 
al., 2009, Michaud et al., 2011) and anti-tumour immunity (Chiba 
et al., 2012), respectively. 
Secreted ATP, is a potent short-range ‘find me’ signal (Elliott et 
al., 2009), that can bind ionotropic (P2X) as well as metabotropic 
(P2Y) purinergic receptors (Elliott et al., 2009, Ghiringhelli et al., 
2009). Secreted ATP has also been observed to help in DC ac-
tivation (Ghiringhelli et al., 2009). During ICD, secreted ATP has 
been reported to bind to the P2X7 receptors, causing activation 
of the NLRP3 inflammasome (Ghiringhelli et al., 2009), which in 
turn mediates caspase-1-mediated processing and secretion of 
IL-1b, a crucial cytokine in the stimulation of antitumor immunity 
(Ghiringhelli et al., 2009). ICD-based secreted ATP has also been 
reported to mediate intratumoural recruitment and differentiation 
of antigen presenting CD11c+CD11b+Ly6chi cells (Ma et al., 2013). 
Interestingly, it has been observed recently that extracellular ATP 
in a tissue context can reduce T cell mobility thereby allowing 
better tissue scanning by T cells (Wang et al., 2014); however, 
the implications of this observation for ICD are not clear yet. It is 
noteworthy that, beyond ATP, secretion of uric acid (UA) (Behrens 
et al., 2008) can also activate the NALP3 inflammasome (Martinon 
et al., 2006). However, the association between UA and apoptosis 
has not been established yet (Behrens et al., 2008). It would be 
interesting to study the impact of UA on cancer immunotherapy 
since increased UA production has been found to mediate tumour 
immune rejection (Hu et al., 2004).
Intriguingly, it has been recently observed that release of nucleic 
acids, like DNA, as DAMPs from dying cells following chemotherapy 
can efficiently instigate an antigen-specific anticancer immune 
response (Chiba et al., 2012). However, whether these kind of 
responses or other such end-stage degradation products e.g. 
mitochondrial DNA and N-formyl peptides (Krysko et al., 2011), 
are also crucial for ICD remains an enigmatic question. 
Secretion or release of endogenous Toll-like receptor (TLR)-
agonists
Release of endogenous ligands binding to TLR4 has been 
found to be critical for ICD (Garrido et al., 2011). Cancer cells 
are capable of releasing various endogenous TLR4-agonists like 
HSP60, HSP70, HSP96, HMGB1 and b-defensin 2 (Apetoh et al., 
2007b). However in the context of chemotherapy-induced ICD only 
passively released high-mobility group box 1 (HMGB1) protein was 
detected (Apetoh et al., 2007b, Krysko et al., 2012). 
During ICD, released HMGB1 binds toll-like receptor (TLR)-4 on 
DCs and, on one hand, activates production of pro-inflammatory 
cytokines yet on the other hand assists in proper antigen-presen-
tation (Apetoh et al., 2007b, Kroemer et al., 2013). Interestingly, 
extracellular HMGB1 has also been found to suppress the activity 
of the immunosuppressive Treg cells (Zhu et al., 2011).
However, there are several contradictory observations regard-
ing the role of HMGB1 in tumourigenesis; because HMGB1 can 
exhibit a redox-dependent switch in functionality or exert effects 
on other stromal cells (e.g. endothelial cells) rather than specific 
effects on immune cells, thereby making it hard to draw steadfast 
conclusions (Jube et al., 2012, Palumbo et al., 2004). It should be 
noted however that, HMGB1 is not the only endogenous TLR4-
agonist that can be released by cancer cells undergoing ICD. For 
instance, human bladder carcinoma cells undergoing ICD induced 
by Hyp-PDT were observed to release HSP70 and HSP90 (Garg 
et al., 2013c, Garg et al., 2012c). Interestingly, it has been ob-
served that extracellular HSP90 can suppress the activity of the 
immunosuppressive cytokine, TGF-b (Suzuki and Kulkarni, 2010).
Down-regulation of CD47: a determinant or a bystander to ICD?
In the context of ICD, ecto-CRT and in certain extended contexts 
ecto-HSP90 and/or ecto-HSP70, can together breach the phagocytic 
barrier and increase the susceptibility of dying/dead cancer cells 
to opsonisation by the mononuclear phagocyte system (MPS). 
The phagocytic barrier, in general, is maintained by a balance 
between “eat me” and “don’t eat me” signals (Chao et al., Gardai 
et al., 2005, Gregory and Brown, 2005). In normal conditions, 
cells possess higher “don’t eat me” signals and thus maintain a 
phagocytic barrier – a strategy utilized by many tumour cells by 
up regulating the prototypical “don’t eat me” signal, CD47 (Chao 
et al., Gardai et al., 2005, Gregory and Brown, 2005). 
However, it has been reported that in the context of general 
apoptosis, cells tend to “loose” their CD47 levels which in the 
context of ICD can be paralleled by increased ecto-CRT thereby 
allowing phagocytic access to MPS (Johansen and Brown, 2007). 
Thus, suppression of the ‘don’t eat me’ signal is crucial for ecto-
CRT to act as an ‘eat me’ signal (Chao et al., Gardai et al., 2005, 
Gregory and Brown, 2005). However, as far as ICD is concerned, 
it is not yet clear whether CD47 suppression plays a direct role in 
regulating the immunogenicity of dying cells or it is just a bystander 
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effect. Only Hyp-PDT based ICD has been reported so far to be 
associated with early loss of CD47 levels (Garg et al., 2012c) – 
however the effect of this on phagocytosis was not investigated.
Danger signalling pathways: mechanistic determinant 
of immunogenic cell death
The ability of ICD-inducing therapies to cause emission of DAMPs 
associates with their capability of activating danger signalling in the 
stressed or dying cancer cells. During ICD, the emission of DAMPs 
by the stressed or dying cells occurs in spatiotemporally-defined 
fashion, largely governed by the activation of danger signalling 
pathways, during which stressed/dying cells surface expose CRT 
in the pre-apoptotic phase (e.g. before phosphatidylserine exter-
nalization), actively secrete ATP (either during pre-apoptotic stage 
or during the blebbing phase) and ultimately release HMGB1, 
post-apoptotically (e.g. during secondary necrosis). 
Evidence from recent biochemical and cellular studies have 
validated the pivotal role of endoplasmic reticulum (ER) stress 
responses; either coupled to the concurrent production of ROS 
(e.g. for most Type I ICD inducers like chemotherapy), or nurtured 
by the on-target generation of ROS at the ER (e.g. for Type II ICD 
inducers like Hyp-PDT), for the extracellular trafficking of DAMPs. 
The requirement for the co-existence of threshold levels of ROS 
and ER stress for the activation of the danger signalling machinery 
eliciting ICD, has been established in different studies (Ghiringhelli 
et al., 2009, Panaretakis et al., 2009), which demonstrated that the 
immunogenicity of the dying cells is severely compromised in the 
presence of anti-oxidants or in the absence of a robust ER stress 
response. Thus, cisplatin, a genotoxic agent that induces changes 
in redox metabolism but fails to induce ER stress, was found to 
evoke ICD only in combination with thapsigargin or tunicamycin 
(Martins et al., 2011). Similarly, melphalan, an anti-melanoma 
chemotherapeutic was unable to induce threshold levels of ROS-
based ER stress necessary for ecto-CRT induction, a defect that 
was corrected by combining with only thapsigargin but not certain 
other ER stressors (Dudek-Peric et al., 2015).
It should be mentioned that although ecto-CRT may also occur 
in apoptotically dying cells as a result of general exposure of ER 
chaperones and ER and Golgi membranes on the cell surface 
(Krysko et al., 2012), during ICD, surface exposure of CRT is an 
active process that precedes the morphological signs of apopto-
sis. Elegant studies have shown that CRT exposure in response 
to anthracyclines, like doxorubicin and mitoxanthrone, requires 
cotranslocation of ERp57 and relies on a complex pathway consist-
ing of the sequential activation of three signalling modules: (a) an 
ER stress-ROS module consisting of the activation of the PERK-
eIF2a axis; (b) an apoptotic module, reliant on the pre-apoptotic 
caspase-8-mediated cleavage of BAP31 and regulated by BAX/
BAK and Ca2+ signals; and (c) a SNARE-dependent, ER-to-Golgi 
anterograde transport (Panaretakis et al., 2009). Furthermore, a 
systematic comparison of the molecular effectors of the DAMP 
trafficking mechanisms in dying cancer cells in response to an-
thracyclines or Hyp-PDT, revealed that ecto-CRT following Hyp-
PDT occurs independently of ERp57 co-translocation and relies 
distinctively on PERK-regulated secretory pathway, BAX/BAK and 
an intact ER-to-Golgi anterograde transport, whereas, in contrast 
to anthracyclines, is independent of eIF2a phosphorylation, Ca2+ 
and caspase-8, or caspase signalling in general (Garg et al., 
2012b, Garg et al., 2012c). This study revealed also that both ICD 
inducers require a PI3K-mediated distal secretory pathway to emit 
ecto-CRT (Garg et al., 2012c). Importantly, in the case of Hyp-PDT, 
active ATP secretion occurred concomitantly to ecto-CRT and was 
governed by similar PERK-regulated proximal secretory pathway 
and PI3K-dependent exocytosis mechanisms (Garg et al., 2012c). 
This study thus unravelled that the activation of a unique danger 
signalling pathway, depending largely on house-keeping processes, 
is responsible for the simultaneous and coordinated emission of 
two DAMPs in this ICD scenario and highlighted the dispensability 
of certain auxiliary molecular effectors, like eIF2a and caspases, 
for the emission of DAMPs after Hyp-PDT. 
This finding is also interesting considering that the active re-
lease of ATP from dying cells in response to UV, anti-CD95/FAS 
therapy (Elliott et al., 2009) and chemotherapy (Martins et al., 2014) 
usually occurs during the early-intermediate phases of apoptosis 
(e.g. blebbing phase) and involves pannexin-1-dependent (Elliott 
et al., 2009) or autophagy-dependent ATP secretion pathways 
(Martins et al., 2014), which are both reliant on caspase activity. 
In the case of mitoxanthrone and oxaliplatin, ATP release from 
dying cancer cells was shown to be inhibited by the knockdown 
of essential autophagy-related genes (ATG5, ATG7 and BECN1), 
such that reducing extracellular ATP levels during ICD compromised 
tumour-specific immune response in vivo (Michaud et al., 2011). 
However, the role of autophagy in the modulation of danger sig-
nalling during ICD appears to be also largely context-dependent. 
While chemotherapy-induced ICD exploits the trafficking properties 
of the autophagy machinery to mobilize ATP, but does not affect 
ecto-CRT (Michaud et al., 2011); autophagy during Hyp-PDT acts 
apically as a cytoprotective degradation mechanism that assists in 
the removal of the excessive amount of oxidized proteins (includ-
ing ER chaperones such as CRT) generated by Hyp-PDT, thereby 
reducing ecto-CRT, without affecting the trafficking and release of 
ATP (Garg et al., 2013a, Garg et al., 2013c, Martin et al., 2015). 
Moreover, recently it was also observed that NDV-induced ICD is 
not associated with the release of extracellular ATP despite the 
induction of autophagy in NDV-treated cancer cells (Koks et al., 
2015). These latter observations reveal the overall complexity of 
ATP secretion pathways and disapprove a proportional relationship 
between autophagy induction and ATP secretion in all ICD contexts.
Hence, all together these studies indicate that the danger signal-
ling underlying the mobilization of crucial DAMPs, like ecto-CRT 
and secreted ATP, in response to anticancer therapy is subjected, 
at least in part, to the type of the cell death stimulus and the mo-
lecular nature and mediators of the danger signalling it instigates. 
This notion needs to be considered in future clinical studies when 
anticancer agents may be combined with modulators of cell stress 
pathways, such as autophagy, which are clinically available.
In spite of the substantial mechanistic information acquired 
on the pathways evoking danger signalling, certain gaps-in-the-
knowledge still need to be filled. For example, it still remains 
enigmatic why concomitant ER stress and ROS production are 
so intricately central for the activation of danger signalling dur-
ing ICD. While the oxidative module may be required to drive 
oxidation-mediated changes in the structures/epitopes of certain 
endogenous biomolecules, a process that might shift their status 
from a “self” to a more “non-self or danger evoking” one, thereby 
increasing their perception by the immune cells (Chang et al., 
2004, Chiang et al., 2008), it is peculiar that out of the three ER 
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stress sensors, i.e. PERK, IRE1 and ATF6, only the activation or 
presence of PERK is critical for DAMP emission. One intriguing 
possibility is that PERK, besides playing an essential role in physi-
ological and pathological secretion (Garg et al., 2012c, Gupta et al., 
2010), is a key mediator of the antiviral response caused by loss 
of proteostasis and ER stress upon viral infection (Zhang et al., 
2014). Consistent with this view, emerging data suggest that ICD 
shares key danger signalling pathways with viral infection (Garg et 
al., 2014). The observation that ICD can be instigated by certain 
oncolytic viruses (Vacchelli et al., 2013), supports this notion. 
Interestingly, a recent elegant study reported that during ER 
stress, misfolded glycosylphosphatidylinositol-anchored proteins 
tend to engage an ER escape mechanism, involving the ER-export 
receptor Tmp21, through which they enter the secretory pathway 
and are temporally exported to the cell surface (Satpute-Krishnan 
et al., 2014). However, whether this phenomenon plays any 
role in the ER stress-induced DAMPs emission needs further 
confirmation. Additionally, a recent study revealed the contribu-
tion of a phylogenetically conserved stress pathway reliant on 
chemokine (C-X-C motif) ligand 8 (CXCL8), also known as IL-8, 
to the exposure of chemotherapy-induced ecto-CRT (Sukkurwala 
et al., 2014b). This suggests that the efficient redistribution of 
CRT on the surface of dying cells may be facilitated or amplified 
by soluble factors acting in an autocrine (or paracrine) manner. 
However, we have recently observed that Hyp-PDT treatment 
does not induce IL-8 secretion in cancer cells thereby making 
IL-8 dispensable for Hyp-PDT induced ecto-CRT (Dudek-Peric 
et al., 2015). This further shows that danger signalling pathways 
cannot be generalized to all ICD inducers based on investigations 
done for a particular class of therapies (e.g. chemotherapy); such 
that while some ‘core’ danger signalling modules might be shared 
amongst all ICD inducers (e.g. PERK activity) yet certain other 
modules might be more ‘private’ for each inducer (e.g. caspase-8 
for chemotherapy) (Garg et al., 2012a).
Immunological and operational determinants of im-
munogenic cell death
Innate and adaptive immune system stimulation
DAMPs associated with ICD exert strong immunostimulatory 
effects upon binding to their respective receptors on immune 
cells, like pattern recognition receptors, scavenging receptors or 
purinergic receptors expressed by immune cells (Zitvogel et al., 
2010). DAMPs and other modifications brought about by the ICD 
inducers helps them in establishing a productive interface between 
dying/dead cancer cells and the immune system. Research has 
clearly shown that on various molecular and certain immunological 
levels, Type II ICD inducers might have some advantages over 
Type I ICD inducers e.g. fast kinetics of DAMPs mobilization lead-
ing to a highly DAMP-enriched pre-apoptotic stage, associated 
with a highly productive interface between dying cancer cells and 
dendritic cells (DCs), devoid of immunosuppressive molecules like 
IL10, and strong tumour microenvironment “resetting” ability (Garg 
et al., 2014, Koks et al., 2015, Krysko et al., 2012). 
The interface between cancer cells undergoing ICD and the im-
mune system has been analyzed in details, for both mice as well as 
human settings, for only a hand full of ICD inducers which include 
mainly anthracyclines or oxaliplatin, radiotherapy and Hyp-PDT. 
These studies have shown that, cancer cells undergoing ICD are 
capable of attracting DCs and certain specific DC subsets mainly 
via secreted ATP (but possible also via HMGB1). Once attracted, 
DCs interacting with cancer cells experiencing ICD undergo ef-
ficient stimulation, “differentiating” into fully mature immunogenic 
DCs overexpressing various surface maturation markers like 
CD80, CD83, CD86 and MHC-II accompanied by production of 
immunostimulatory cytokines or factors like IL1b, nitric oxide, 
IL12p70, IL6 in absence of or decrease occurrence of IL10 (at 
least for Hyp-PDT) (Apetoh et al., 2007a, Casares et al., 2005, 
Fucikova et al., 2011, Garg et al., 2013c, Garg et al., 2012c, Obeid 
et al., 2007). This APC/DC-level activations generally proceed 
into two sequential phases i.e. recruitment of T cells followed by 
their activation into IL-17-secreting gδ T cells, ab Th1 cells (IFN-g 
secreting CD4+ T cells) and ab cytotoxic T cells (IFN-g secreting 
CD8+ T cells) (Fucikova et al., 2011, Garg et al., 2013c, Ma et al., 
2011, Mattarollo et al., 2011, Michaud et al., 2011). The latter are 
not only capable of mediating direct antitumourigenic effects but 
also underlie the establishment of host-protective immunological 
memory. Of note, comprehensive studies on the effect of ICD on 
macrophages, Th17 cells and Treg cells are still lacking and re-
quire attention in future. Moreover, most of the above results are 
derived either from ex vivo immune cell co-culture experiments 
or analysis of heterotropic subcutaneous tumours. In future there 
is an urgent need to extend these studies to either spontaneous 
tumour models or orthotopic tumour models. 
Tumour-rejecting immunity in a vaccination context
Almost a decade-long list of published research has character-
ized various molecular, mechanistic and immunological determi-
nants of ICD; however, the gold-standard approach to evaluate 
the ability of a specific agent or modality to elicit bona fide ICD 
still relies on vaccination assays showing tumour-rejecting capa-
bilities of the immunized host (Casares et al., 2005, Kroemer et 
al., 2013). In this setting, the cancer cells are treated in vitro with 
the drug/agent/modality/therapy under consideration and then 
injected either intraperitoneally or subcutaneously/intradermally 
into the flank of immunocompetent syngeneic rodents, followed 
by a re-challenge with living cells of the same cancer type into 
the opposite flank or another site-of-choice for the tumour. The 
proportion of rodents that resist such subcutaneous tumours 
reveal the degree of immunogenicity of cell death for the therapy 
under consideration (in case of prototypical ICD inducers like 
anthracyclines or Hyp-PDT, this happens for 90-70% of mice, 
although strain-to-strain, cancer type-to-cancer type and setup-
to-setup differences can exist) (Garg et al., 2012c, Menger et al., 
2012, Obeid et al., 2007).
Conclusion and future perspective
There are several challenges ahead of which four stand-out. 
Firstly, ICD needs to be translated to advanced rodent models. 
Secondly, rodent models exhibiting naturally-occurring defects in 
ICD need to be characterized in order to identify intrinsic natural-
defects that may “de-rail” ICD. The only scenario so far charac-
terized in this direction is defects on the level of TLR4 mutations 
however cancer cell-level defects remain elusive. Thirdly, there is 
an impending need to differentiate between false positive and bona 
fide ICD inducers. Drugs or modalities that are characterized to 
only induce ICD-associated DAMPs (i.e. molecular determinant) 
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in vitro but not ICD-associated immunological determinants (ex 
vivo or in vivo) and/or its operational determinant (i.e. anti-cancer 
vaccination effect, in vivo) cannot reliably be categorized as bona 
fide ICD inducers. This is especially applicable to agents that do 
not induce proper spatiotemporally defined DAMPs emission pat-
tern associated with ICD (i.e. pre-apoptotic ecto-CRT/ecto-HSP90, 
pre- or early-apoptotic secreted ATP and mid- or post-apoptotic 
release of HMGB1/HSP70/HMGB1). In such cases it is hard to 
differentiate between the bystander presence of these DAMPs 
and their actual ICD-associated functions. Of note, ecto-CRT is 
the most important ICD-DAMP since its presence is universal to all 
ICD inducers while ATP or HMGB1 may or may not be present in 
certain ICD contexts e.g. despite autophagy induction, Newcastle 
disease virus-induced ICD is devoid of secreted ATP (Koks et al., 
2015); similarly, in the human bladder cancer context, the bona 
fide ICD inducer, Hyp-PDT is not able to induce HMGB1 release 
(Garg et al., 2013c, Garg et al., 2012c). Thus, only analysis of 
molecular determinants is not reliable for ICD characterization. 
To this end, the analysis of ICD-DAMPs should be considered 
secondary to in vivo immunological or vaccination analysis and/
or ex vivo immunological analysis (involving both DCs and T 
cells), in order to conclude that a given drug/modality is an ICD 
inducer. These rigorous standards, if maintained, would allow 
proper characterization of new ICD inducers while eliminating the 
possibility of false positives. Last but not least, there is an urgent 
need to characterize the impact of ICD in the clinic and to identify 
ICD-related biomarkers capable of predicting the likelihood of a 
patient to respond to anticancer therapies that engage the host’s 
immune system.
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